Shmulik Hess

Shmulik Hess is an accomplished professional in the biotechnology and pharmaceutical sectors, currently serving as Chief Operating Officer and Chief Commercial Officer at MediWound since November 2023. Prior to this role, Shmulik co-founded and served as CEO of Tabby Therapeutics from May 2020 to November 2023 and held the position of CEO at Enlivex Therapeutics from November 2018 to December 2019, focusing on immunotherapy innovations. Shmulik's extensive experience also includes leadership roles at Valin Technologies, Active P, and a member of the executive board for ScienceAbroad. Educational qualifications include a PhD in Pharmaceutical Sciences from The Hebrew University of Jerusalem, alongside degrees in Emergency Medicine from Ben-Gurion University of the Negev.